Technology evaluation: Gemtuzumab ozogamicin, Celltech Group

Current Opinion in Molecular Therapeutics

Volumn 2, Issue 6, 2000, Pages 691-696

  Niculescu Duvaz, I ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; CD33 ANTIGEN; CDP 771; CYTOTOXIC AGENT; GEMTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BIOTECHNOLOGY; BONE MARROW HYPOPLASIA; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CLINICAL TRIAL; CYTOTOXICITY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; GRANULOCYTOPENIA; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; STRUCTURE ACTIVITY RELATION;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; BONE MARROW; HUMANS; IMMUNOTOXINS; LEUKEMIA, MYELOCYTIC, ACUTE; MICE; SAFETY;

EID: 0034535041     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Celltech's promising leukaemia results
2. Investigational compound from Wyeth-Ayerst and Celltech offers promise for AML patients in early clinical trials
3. Europe: Biotechnology
4. Preliminary announcement of results for the year ended 30 September 1998
5. Interim analysis of the efficacy and safety of CMA-676 in patients with AML in first relapse
6. Breakthrough new therapy uses antibody-targeted chemotherapy to fight leukemia Fred Hutchinson Cancer Research Center researchers present study results at the American Society of Clinical Oncology meeting in Atlanta
7. Preliminary results of the efficacy and safety of CMA-676 in patients with AML in first relapse
8. European Biotechnology Research: Celltech plc.
9. Celltech/Wyeth-Ayerst to file CMA-676 NDA in third quarter
10. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD22 calichemacin immunoconjugate
11. US NDA submitted for acute myeloid leukemia treatment
12. Antibody-targeted chemotherapy with CMA-676 uses breakthrough technology to treat leukemia
13. American Society of Hematology 41st Annual Meeting (Part V), New Orleans, LA, USA
14. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (CMA-676) shows non-apoptotic cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotsin-expressing sublines
15. Efficacy and safety of CMA-676 in patients with AML in first relapse
16. In vivo targeting of the humanized CD33 antibody CMA-676 in AML patients: Rapid saturation and internalization by leukemic blasts and normal myeloid cells
17. FDA accepts and designates priority status to American Home Products Corporation's novel treatment for relapsed adult acute myeloid leukemia - Mylotarg offers first glimpse of promising oncology pipeline
18. Lehman Brothers: Biotechnology United Kingdom: Celltech.
19. FDA Advisory Committee recommends approval of first antibody-targeted chemotherapy - American Home Products' Mylotarg emerging from oncology pipeline
20. US drug industry RX insight - American Home Products Corp.
21. Press Releases - New product pipeline
22. A population pharmecokinetic analysis of gemtuzumab zogamicin: A new antibody chemotherapeutic agent
23. American Home Products gains FDA approval for Mylotarg; First antibody-targeted chemotherapy provides high tech cancer-fighting option
24. Protein Design Labs announces exercise of patent license option by American Home Products
25. Comparison of the efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients < 60 and > 60 years of age with AML in first relapse
26. Celltech Group plc - Interim report for the six months ended 30th June 2000
27. Pharmaceutical models: Europe
28. Monoclonal antibodies to the myeloid stem cells: Therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate
29. Dose escalation phase I study of recombinant engineered human anti-CD33 antibody-calicheamicin drug conjugate (CMA-676), in patients with relapsed or refractory acute myeloid leukemia
30. Selective ablation of acute myeloid leukemia using an anti-CD33 calicheamicin immunoconjugate